Kowalczyk Karolina, Radosz Patrycja, Barański Kamil, Pluta Dagmara, Kowalczyk Dariusz, Franik Grzegorz, Madej Paweł
Department of Endocrinological Gynaecology, Faculty of Medicine in Katowice, Medical University of Silesia, Katowice 40-752, Poland.
Department of Epidemiology, Faculty of Medicine in Katowice, Medical University of Silesia, Katowice 40-752, Poland.
Int J Endocrinol. 2021 Nov 29;2021:8427150. doi: 10.1155/2021/8427150. eCollection 2021.
Polycystic ovary syndrome (PCOS) and hypothyroidism are the most common endocrinological disorders among women of reproductive age. Since hypothyroidism occurs more frequently in PCOS patients, it is vital to explain its clinical impact.
To evaluate the impact of subclinical hypothyroidism (SCH) and its treatment on the metabolic profile of patients with PCOS.
190 women with PCOS phenotype A were enrolled in the case-control study. They were divided into three groups: 38 women with PCOS and subclinical hypothyroidism, 76 women with PCOS and SCH under thyroid replacement therapy, and 76 women with PCOS and normal thyroid function (control group). Serum lipids, fasting glucose, and insulin, as well as oral glucose tolerance tests were performed.
In the analyzed parameters, there were no statistic differences between the groups in relation to thyroid function. BMI turned out to be the main factor dividing the patients in terms of serum lipids, fasting glucose, fasting insulin, and oral glucose tolerance test. TSH was associated with total cholesterol and LDL cholesterol levels, whereas BMI has a dominant impact on HDL cholesterol, triglycerides, glucose, and insulin resistance.
SCH is associated with mild lipid serum alterations in women with PCOS, but it is BMI to have a dominant impact on glucose and insulin. It seems that treatment of SCH in PCOS does not significantly alter lipid and glucose metabolism.
多囊卵巢综合征（PCOS）和甲状腺功能减退是育龄女性中最常见的内分泌疾病。由于甲状腺功能减退在PCOS患者中更频繁发生，解释其临床影响至关重要。
评估亚临床甲状腺功能减退（SCH）及其治疗对PCOS患者代谢谱的影响。
190例具有PCOS A型表型的女性被纳入病例对照研究。她们被分为三组：38例患有PCOS和亚临床甲状腺功能减退的女性，76例患有PCOS且在甲状腺替代治疗下的SCH女性，以及76例患有PCOS且甲状腺功能正常的女性（对照组）。进行了血脂、空腹血糖和胰岛素检测以及口服葡萄糖耐量试验。
在所分析的参数中，各组在甲状腺功能方面无统计学差异。BMI是根据血脂、空腹血糖、空腹胰岛素和口服葡萄糖耐量试验来区分患者的主要因素。促甲状腺激素（TSH）与总胆固醇和低密度脂蛋白胆固醇水平相关，而BMI对高密度脂蛋白胆固醇、甘油三酯、血糖和胰岛素抵抗有主要影响。
SCH与PCOS女性的轻度血脂改变有关，但对血糖和胰岛素起主要影响的是BMI。PCOS患者中SCH的治疗似乎不会显著改变脂质和葡萄糖代谢。
